Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China

• المؤلفون الرئيسيون: Yamin Shu (مؤلف), Yufeng Ding (مؤلف), Xucheng He (مؤلف), Yanxin Liu (مؤلف), Pan Wu (مؤلف), Qilin Zhang (مؤلف)
• التنسيق: كتاب
• منشور في: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Objective: The purpose of this study was to estimate the cost-effectiveness of osimertinib for the first-line treatment of patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC) from the perspective of the Chinese healthcare system.Methods: A Markov model was developed to simulate th...